By Drug Target Review2026-04-16T09:00:00
Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T cell therapy. The collaboration will combine Circio’s technology, which reportedly delivers gene expression lasting up to six months in lymphocytes, with Acuitas’ lipid nanoparticle delivery system targeting specific T cell populations for potential applications in oncology and autoimmune diseases.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2026-08-03T06:00:00
Author Dr Xiaoxiao Wang, Yan Zhang and Junli Zhao
2026-08-24T08:43:00
Author Dr Dana Watt
2026-08-20T08:43:00
Author Dr Daniel Tillett
2025-11-19T16:00:00
Sponsored by Eurofins DiscoverX
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2026-11-20T08:00:00
Contributor Dr Rahul Gupta, By Drug Target Review
Site powered by Webvision Cloud